Polls

Are you open to recommending an SGLT-2 inhibitor as a second drug for a patient with type 2 diabetes who is overweight and has not met their goal? Follow the link to see how you compare to your colleagues.

What do you use to diagnose prediabetes a majority of the time? 1) HbA1c 2) Fasting BG 3) IGTT 4) Other Follow the link to see how you compare to your colleagues.

When recommending an insulin pen to a patient, do you have sample pens to demonstrate how to use properly? Follow the link to see how you compare to your colleagues.

For a 2nd add-on drug to prescribe to those with type 2 diabetes and who are not meeting either an A1c goal of 6% or less, or an A1c of 7.5% with no complications, which might you prefer to add on to metformin to reach the goal of 6%? 1. DPP-4 Inhibitor 2. SGLT-2 Inhibitor 3. TZD 4. Sulfonylurea 5. Dopamine receptor agonist 6. GLP-1 Agonists Follow the link to share your response.

Which new drug do you prefer for a second-line therapy for a patient with type 2 patient diabetes? 1) GLP-1 Agonist 2) SGLT-2 Inhibitor 3) Long-acting insulin 4) TZD 5) Other Follow the link to share your response.

Do you feel that continuous blood glucose monitoring (CGM) will eventually replace blood glucose monitors? Follow the link to share your response.

Can most of your patients with diabetes or prediabetes tell you what their A1c number is? Follow the link to share your response.

What percentage of your prediabetes patients do you recommend a pharmaceutical treatment? 1. 10-25% 2. 25-50% 3. Greater than 50% 4. Zero. I only recommend diet and exercise. Follow the link to share your response.

Because the A1c test is important for more than diagnosing diabetes and prediabetes, it is important that we each know what our A1c is. Do you know what your A1c number is? Follow the link to share your response!

How often do you recommend to your type 2 patients who are not on insulin to monitor their blood sugars daily? 1. Once a day 2. Twice a day 3. More than twice a day 4. Once a week or Less than daily Follow the link to share your response.